Safety and effectiveness of dulaglutide in Chinese adults with type 2 diabetes mellitus in a real-world setting: A prospective, observational post-marketing study.

Guo L, Li L, Yu Q, Wang N, Chen J, Xi Y, Wang H, Wang Y, Xu J

Diabetes, obesity & metabolism23 Aug 2023Cited by 3 (Europe PMC)

PMID37612876DOI10.1111/dom.15252PepBankPUB-37612876

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study11

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studySafety outcome
Among Chinese adults receiving dulaglutide, treatment-emergent adverse events occurred in 1333 patients, or 40.5%.
In plain wordsAmong Chinese adults receiving dulaglutide, 40.5% reported treatment-emergent adverse events.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableTreatment-emergent adverse events
Study
n = 3,291
Analysis
Primary
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · up to 24 weeksAs given in this study (human).
Measurements
Patients with TEAEs
1333 patients
dulaglutide
TEAE incidence
40.5%
dulaglutide
Source sentences
Summary
TEAEs were reported in 1333 (40.5%) patients;
3 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint was the incidence of treatment-emergent adverse events (TEAEs) and serious AEs in patients who received ≥1 dose of dulaglutide, for up to 24 weeks.
Summary · context
From 20 January 2020 to 24 November 2021, 3291 patients received dulaglutide and entered the safety analysis.
Summary · context
This prospective, observational, post-marketing study conducted at 46 hospitals in China included adults with T2DM prescribed dulaglutide in routine clinical practice.
Report a problemFND-3761287601
02HumanObservational studySafety outcome
Among Chinese adults receiving dulaglutide, serious adverse events occurred in 160 patients, or 4.9%.
In plain wordsAmong Chinese adults receiving dulaglutide, 4.9% reported serious adverse events.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableSerious adverse events
Study
n = 3,291
Analysis
Primary
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · up to 24 weeksAs given in this study (human).
Measurements
Serious AE patients
160 patients
dulaglutide
Serious AE incidence
4.9%
dulaglutide
Source sentences
Summary
serious AEs were reported in 160 (4.9%) patients.
3 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint was the incidence of treatment-emergent adverse events (TEAEs) and serious AEs in patients who received ≥1 dose of dulaglutide, for up to 24 weeks.
Summary · context
From 20 January 2020 to 24 November 2021, 3291 patients received dulaglutide and entered the safety analysis.
Summary · context
This prospective, observational, post-marketing study conducted at 46 hospitals in China included adults with T2DM prescribed dulaglutide in routine clinical practice.
Report a problemFND-3761287605
03HumanObservational studyEfficacy outcome
In Chinese adults with T2DM, dulaglutide use was associated with a mean HbA1c change of -1.65% at week 24.
In plain wordsIn Chinese adults with diabetes, dulaglutide use was linked to lower HbA1c at week 24 than at baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change
Study
n: not reported in source
Comparator
Baseline
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · up to 24 weeksAs given in this study (human).
Measurements
HbA1c change
−1.65%
baseline to week 24
Source sentences
Summary
The mean absolute change in HbA1c from baseline to week 24 was -1.65% (p < .001).
2 context sentences(design, population, supporting numbers)
Summary · context
Exploratory endpoints included changes in patient-reported glycated haemoglobin (HbA1c) and body weight.
Summary · context
This prospective, observational, post-marketing study conducted at 46 hospitals in China included adults with T2DM prescribed dulaglutide in routine clinical practice.
Report a problemFND-3761287607
04HumanObservational studyEfficacy outcome
In Chinese adults with T2DM, dulaglutide use was associated with a mean weight change of -2.62 kg at week 24.
In plain wordsIn Chinese adults with diabetes, dulaglutide use was linked to lower weight at week 24 than at baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight change
Study
n: not reported in source
Comparator
Baseline
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · up to 24 weeksAs given in this study (human).
Measurements
Weight change
−2.62 kg
baseline to week 24
Source sentences
Summary
The mean absolute change in body weight from baseline at week 24 was -2.62 kg (p < .001).
2 context sentences(design, population, supporting numbers)
Summary · context
Exploratory endpoints included changes in patient-reported glycated haemoglobin (HbA1c) and body weight.
Summary · context
This prospective, observational, post-marketing study conducted at 46 hospitals in China included adults with T2DM prescribed dulaglutide in routine clinical practice.
Report a problemFND-3761287611
05HumanObservational studySafety outcome
Among Chinese adults receiving dulaglutide, nausea occurred in 193 patients, or 5.9%.
In plain wordsAmong Chinese adults receiving dulaglutide, 5.9% reported nausea.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableNausea
Study
n = 3,291
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · up to 24 weeksAs given in this study (human).
Measurements
Nausea patients
193 patients
dulaglutide
Nausea incidence
5.9%
dulaglutide
Source sentences
Summary
the most commonly reported were nausea (n = 193, 5.9%), diarrhoea (n = 183, 5.6%) and decreased appetite (n = 179, 5.4%).
3 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint was the incidence of treatment-emergent adverse events (TEAEs) and serious AEs in patients who received ≥1 dose of dulaglutide, for up to 24 weeks.
Summary · context
From 20 January 2020 to 24 November 2021, 3291 patients received dulaglutide and entered the safety analysis.
Summary · context
This prospective, observational, post-marketing study conducted at 46 hospitals in China included adults with T2DM prescribed dulaglutide in routine clinical practice.
Report a problemFND-3761287602
06HumanObservational studySafety outcome
Among Chinese adults receiving dulaglutide, diarrhoea occurred in 183 patients, or 5.6%.
In plain wordsAmong Chinese adults receiving dulaglutide, 5.6% reported diarrhoea.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableDiarrhoea
Study
n = 3,291
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · up to 24 weeksAs given in this study (human).
Measurements
Diarrhoea patients
183 patients
dulaglutide
Diarrhoea incidence
5.6%
dulaglutide
Source sentences
Summary
the most commonly reported were nausea (n = 193, 5.9%), diarrhoea (n = 183, 5.6%) and decreased appetite (n = 179, 5.4%).
3 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint was the incidence of treatment-emergent adverse events (TEAEs) and serious AEs in patients who received ≥1 dose of dulaglutide, for up to 24 weeks.
Summary · context
From 20 January 2020 to 24 November 2021, 3291 patients received dulaglutide and entered the safety analysis.
Summary · context
This prospective, observational, post-marketing study conducted at 46 hospitals in China included adults with T2DM prescribed dulaglutide in routine clinical practice.
Report a problemFND-3761287603
07HumanObservational studySafety outcome
Among Chinese adults receiving dulaglutide, decreased appetite occurred in 179 patients, or 5.4%.
In plain wordsAmong Chinese adults receiving dulaglutide, 5.4% reported decreased appetite.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableDecreased appetite
Study
n = 3,291
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · up to 24 weeksAs given in this study (human).
Measurements
Decreased appetite patients
179 patients
dulaglutide
Decreased appetite incidence
5.4%
dulaglutide
Source sentences
Summary
the most commonly reported were nausea (n = 193, 5.9%), diarrhoea (n = 183, 5.6%) and decreased appetite (n = 179, 5.4%).
3 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint was the incidence of treatment-emergent adverse events (TEAEs) and serious AEs in patients who received ≥1 dose of dulaglutide, for up to 24 weeks.
Summary · context
From 20 January 2020 to 24 November 2021, 3291 patients received dulaglutide and entered the safety analysis.
Summary · context
This prospective, observational, post-marketing study conducted at 46 hospitals in China included adults with T2DM prescribed dulaglutide in routine clinical practice.
Report a problemFND-3761287604
08HumanObservational studySafety outcome
Among Chinese adults receiving dulaglutide, treatment-emergent adverse events led to discontinuation in 212 patients, or 6.4%.
In plain wordsAmong Chinese adults receiving dulaglutide, 6.4% stopped treatment because of treatment-emergent adverse events.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableDiscontinuation due to adverse events
Study
n = 3,291
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · up to 24 weeksAs given in this study (human).
Measurements
Discontinuation patients
212 patients
dulaglutide
Discontinuation incidence
6.4%
dulaglutide
Source sentences
Summary
TEAEs led to treatment discontinuation in 212 (6.4%) patients.
2 context sentences(design, population, supporting numbers)
Summary · context
From 20 January 2020 to 24 November 2021, 3291 patients received dulaglutide and entered the safety analysis.
Summary · context
This prospective, observational, post-marketing study conducted at 46 hospitals in China included adults with T2DM prescribed dulaglutide in routine clinical practice.
Report a problemFND-3761287606

Studies that did not test the peptide alone3

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
Among dulaglutide recipients, T2DM duration ≤5 years was associated with greater HbA1c reductions at week 24.
In plain wordsAmong dulaglutide recipients, shorter diabetes duration was linked to greater HbA1c reductions than longer duration.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change by diabetes duration
Study
n: not reported in source
Comparator
Longer T2DM duration
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Greater reductions in HbA1c at week 24 were observed in patients with T2DM duration ≤5 years (p = .002), baseline HbA1c ≥8.5% (p < .001), and without atherosclerotic cardiovascular disease (p = .002).
1 context sentence(design, population, supporting numbers)
Summary · context
This prospective, observational, post-marketing study conducted at 46 hospitals in China included adults with T2DM prescribed dulaglutide in routine clinical practice.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3761287608
10HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
Among dulaglutide recipients, baseline HbA1c ≥8.5% was associated with greater HbA1c reductions at week 24.
In plain wordsAmong dulaglutide recipients, higher starting HbA1c was linked to greater HbA1c reductions than lower starting HbA1c.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change by baseline HbA1c
Study
n: not reported in source
Comparator
Lower baseline HbA1c
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Greater reductions in HbA1c at week 24 were observed in patients with T2DM duration ≤5 years (p = .002), baseline HbA1c ≥8.5% (p < .001), and without atherosclerotic cardiovascular disease (p = .002).
1 context sentence(design, population, supporting numbers)
Summary · context
This prospective, observational, post-marketing study conducted at 46 hospitals in China included adults with T2DM prescribed dulaglutide in routine clinical practice.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3761287609
11HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
Among dulaglutide recipients, absence of atherosclerotic cardiovascular disease was associated with greater HbA1c reductions at week 24.
In plain wordsAmong dulaglutide recipients, absence of atherosclerotic cardiovascular disease was linked to greater HbA1c reductions than its presence.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change by cardiovascular disease
Study
n: not reported in source
Comparator
Atherosclerotic cardiovascular disease present
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Greater reductions in HbA1c at week 24 were observed in patients with T2DM duration ≤5 years (p = .002), baseline HbA1c ≥8.5% (p < .001), and without atherosclerotic cardiovascular disease (p = .002).
1 context sentence(design, population, supporting numbers)
Summary · context
This prospective, observational, post-marketing study conducted at 46 hospitals in China included adults with T2DM prescribed dulaglutide in routine clinical practice.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3761287610

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.